Evidence map›Paper›PMID 40117491›Full record

ReviewBlood advances2025

Venous thrombosis unchained: Pandora's box of noninflammatory mechanisms.

Sophie R M Smith, Neil V Morgan, Alexander Brill

Abstract readReview
In one paragraph

Review in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Mechanisms of Piezo1-Mediated Mechanotransduction in Thrombotic Diseases.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. The Triglyceride-glucose Index Predicts Short-Term Mortality in Critically Ill Patients With Cancer-Associated Thrombosis: A Retrospective Cohort Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sophie R M SmithDepartment of Cardiovascular Sciences, School of Medical Sciences, University of Birmingham, Birmingham, United Kingdom.
Neil V MorganDepartment of Cardiovascular Sciences, School of Medical Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0001-6433-5692
Alexander BrillDepartment of Cardiovascular Sciences, School of Medical Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0002-4558-0390

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractVenous thromboembolism, which includes deep vein thrombosis (DVT) and pulmonary embolism, represents a complex pathological process extending far beyond inflammatory mechanisms. This review comprehensively examines the multifaceted noninflammatory mechanisms underlying thrombosis development, integrating insights from molecular, physiological, and systemic levels. Blood flow dynamics and endothelial function are known to be critical regulators of thrombus development. Platelets and microparticles play important roles beyond conventional inflammatory responses, actively contributing to thrombus formation through intricate molecular interactions. Metabolic syndrome and insulin resistance are associated with thrombotic risk, demonstrating the complex interplay between metabolic disorders and DVT. Certain genetic mutations also predispose individuals to venous thrombosis. Emerging research has discovered the essential role of previously underappreciated factors such as products of gut microbiota or endothelial glycocalyx modifications. Molecular regulators such as microRNAs and hormonal disbalance further illustrate the complex mechanisms of venous thrombosis. Interestingly, circadian rhythms exhibit certain influence on thrombotic potential, introducing chronobiology as an emerging variable affecting the risk of thrombosis. On the basis of these insights, future therapeutic strategies may include various interventions targeting or at least considering metabolic, molecular, and systemic noninflammatory factors. Potential approaches include personalized risk stratification, microbiome modulation, endothelial protection approaches, and chronotherapy-based therapeutic modalities, which would ensure more efficient and safe thrombosis management.

Indexed as

Venous ThrombosisAnimalsDisease SusceptibilityHumansInflammation

Identifiers

PMID40117491
PMCPMC12205585

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.